Clonality markers

Brittain E, Noel P, Metcalfe DD Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with idiopathic anaphy- 72 laxis. Blood 2007 110 2331-2333. 

A, Sidransky D. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res 2002 8 ... 

Water bath at 37°C, for expressing genes linked to a heat shock promoter (hsp e.g., hspFLPase, or the nM, NM, or hsp-CD2 clonal markers)... 

Hepatocellular carcinoma (HCC) develops in patients with chronic liver diseases associated with hepatitis B and hepatitis C vims infections with high incidences. Here, an acyclic retinoid has been shown to suppress the posttherapeutic recurrence after interferon-y or glycerrhicin treatment in cirrhotic patients who underwent curative treatment of preceding tumors. The retinoid induced the disappearance of serum lectin-reactive a-fetoprotein (AFP-L3), a tumor marker indicating the presence of unrecognizable tumors in the remnant liver, suggesting a deletion of such minute (pre)malignant clones (clonal deletion). As a molecular mechanism of the clonal deletion, a novel mechanism of... 

Antithrombin HI in cerebrospinal fluid can be easily denoted as an inflammatory marker. Correlations with levels of immunoglobulins, their intrathecal oligo-clonal synthesis, complement components, and acute-phase reactants confirm such concepts. Correlations with apolipoproteins and with the presence of lipophagic macrophages in cytological preparations confirm the elevation of CSF AT III levels when a destructive lesion of the CNS is present. 

Mitochondrial DNA (mtDNA), which is clonally inherited through maternal lineages, has proved to be a powerful genetic marker for phyloge-... 

Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986 47 883-9. 

It is likely that MFH is not a unified entity in the skin or elsewhere, but instead represents a histologic pattern that is a common final pathway of differentiation for several modes of mesenchymal neoplasia. That concept was first espoused by Brooks. Thus an MFH-like pattern may be seen in conjunction with other mesenchymal images in the same tumor mass, as a consequence of clonal evolution. An unqualified diagnosis of MFH can be made immunohistologically only if one is dealing with a pleomorphic malignant tumor that is vimentin reactive and lacks epithelial, myogenous, neural, and endothelial markers. At present, there are no proactive determinants that define this neoplasm. 

---